 |
BIOX to Showcase at China International Medical Equipment Fair in Shenzhen, China |
April 4, 2012 - WESTBURY, N.Y. - VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the BIOX Instruments Co. Ltd., a subsidiary of VasoMedical, will attend and exhibit at the 69th China International Medical Equipment Fair (CMEF) from April 17-20, 2013 in Shenzhen, China.
The China International Medical Equipment Fair, founded in 1979, is held twice a year during the spring and autumn seasons. It is the largest exhibition of medical equipment, related products and services in the Asia-Pacific region, attracting about 2,600 exhibitors and over 82,000 attendees from more than 100 countries and regions. The exhibition features products from across the medical device industry, including medical imaging, in vitro diagnosis, electronics, optics, first aid, rehabilitation, nursing, medical information technology and outsourcing services, among many others. BIOX has been participating in both spring and autumn events for 18 consecutive years and under VasoMedical brand since last year.
VasoMedical-BIOX will be located at Booth H9-G27 in Hall 9 in the Shenzhen Convention and Exhibition Center. It will present the BIOX line of ambulatory monitoring systems including Holter monitors, ambulatory blood pressure monitors (ABPM), analysis and reporting software, as well as many OEM modules for EEG (electroencephalography), oximeter, etc. VasoMedical's core technology, EECP® Therapy will also be featured in the show.
“Given that BIOX Instruments was recently awarded the Excellent Trusted Enterprises Award (top tier) by the Jiangsu Province State Food and Drug Administration (SFDA) of China, CMEF is well timed for us to further promote our BIOX line of products among customers from regions where we already have strong presence, as well as to increase awareness about this great line of products to expand in the Chinese and international markets,” said Qiuming Shen, president of BIOX Instruments. “With support from our colleagues from New York, we will take the opportunity to also promote VasoMedical's core technology, EECP® Therapy, to Chinese and international customers.”
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
About BIOX Instruments
BIOX Instruments Co., Ltd., a wholly owned subsidiary of VasoMedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. BIOX is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. BIOX products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, BIOX continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at www.biox.com.cn.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com